[1] |
ZHAO Yihan, LI Ruochen, LIN Yansong.
Current status and prospect of diagnosis and treatment of bone metastasis of thyroid cancer
[J]. China Oncology, 2025, 35(1): 12-20.
|
[2] |
ZHANG Zhiyue, HE Huijing, SHAN Guangliang, LIN Yansong.
Research progress in epidemiology and risk factors of thyroid cancer
[J]. China Oncology, 2025, 35(1): 21-29.
|
[3] |
GENG Qianqian, YANG Aimin.
Progress and prospect on treatment for radioiodine-refractory thyroid cancer
[J]. China Oncology, 2025, 35(1): 30-39.
|
[4] |
LI Ruping, YANG Hui.
Current status and future prospects of clinical trials for radioiodine-refractory thyroid cancer
[J]. China Oncology, 2025, 35(1): 40-48.
|
[5] |
WANG Renfei, LU Gaixia.
The unique value and controversy of nuclear medicine molecular imaging in the evaluation of radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 49-57.
|
[6] |
LIN Qiuyu, WANG Yuxin, LIN Chenghe.
Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 58-67.
|
[7] |
SHEN Jie, LIU Wanlin, WANG Zezhou, MU Sibo, MO Miao, ZHOU Changming, YUAN Jing, WANG Yu, ZHENG Ying, JI Qinghai.
Survival and cause-of-death analysis of 55 thousand thyroid cancer cases in China from a large single institution hospital-based cancer registry database
[J]. China Oncology, 2025, 35(1): 68-76.
|
[8] |
JIANG Xiaotong, LIU Jinchuan, ZHANG Yingqiang, WANG Tong, GUO Ning, SUN Yuqing, SHI Cong, YAN Bing, LIN Yansong.
The role of diagnostic whole body scan in decision-making of 131I treatment for differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 77-84.
|
[9] |
PAN Yijin, SHI Cong, SUN Yuqing, SUN Di, ZHAO Yihan, ZHANG Jin, LIN Yansong.
Global trends of 131I-therapy for differentiated thyroid cancer in children and adolescents: a bibliometric analysis (1993-2003)
[J]. China Oncology, 2024, 34(12): 1123-1133.
|
[10] |
XUE Liqiong, GUO Ye, CHEN Libo.
Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer (2023 edition)
[J]. China Oncology, 2023, 33(9): 879-888.
|
[11] |
YUAN Xinyue, YAO Yao, CHENG Shuai, ZHENG Xin, ZHANG Yuan.
Clinical study on high-risk factors for contralateral lymph node metastasis in unilateral papillary thyroid carcinoma
[J]. China Oncology, 2023, 33(6): 619-628.
|
[12] |
QU Ning, WANG Yuting, MA Ben, WANG Yu.
Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022
[J]. China Oncology, 2023, 33(5): 423-430.
|
[13] |
TANG Duocai, ZHOU Shukui, ZHANG Guiyin, LIU Lei, LIAO Hong.
Analysis of risk factors of recurrence in non-muscle invasive bladder cancer patients after initial transurethral resection of bladder tumor
[J]. China Oncology, 2023, 33(5): 478-483.
|
[14] |
CHEN Zhujun, DING Zhimin, MA Xiaolu, WANG Yanchun, HU Haoyun, LU Renquan, GUO Lin.
Analysis of characteristics of infectious pathogens in malignant tumors combined with bloodstream infection and significance of serum glucose detection
[J]. China Oncology, 2023, 33(10): 927-935.
|
[15] |
CAO Mengxuan, HU Can, ZHANG Yanqiang, HUANG Ling, DU Yian, YU Pengcheng, ZHANG Ruolan, XU Zhiyuan, CHENG Xiangdong.
Analysis of risk factors of early recurrence and metastasis after radical resection of gastric cancer
[J]. China Oncology, 2022, 32(7): 588-595.
|